8-KEarnings & Results

BIOGEN INC. 8-K Report, Financial Results (Oct 27, 2004)

Filed October 27, 2004For Securities:BIIB

Summary

Biogen Idec Inc. filed an 8-K on October 27, 2004, primarily to furnish a press release dated the same day, as per Item 2.02 (Results of Operations and Financial Condition). This filing does not contain detailed financial results within the 8-K itself but directs investors to the attached press release for that information. The press release, which is the core of this filing, would typically contain updates on the company's financial performance, operational highlights, and potentially forward-looking statements regarding its business outlook. Investors should review the press release for specifics on revenue, earnings, product performance, and any significant strategic developments or challenges announced on that date.

Key Highlights

  • 1Biogen Idec Inc. filed an 8-K Current Report on October 27, 2004.
  • 2The filing's primary purpose under Item 2.02 is to provide information on Results of Operations and Financial Condition.
  • 3The substantive information is contained within an attached press release (Exhibit 99.1) dated October 27, 2004.
  • 4This press release is furnished and not deemed 'filed' for regulatory liability purposes under Section 18 of the Exchange Act.
  • 5The 8-K itself does not contain the detailed financial results; investors must refer to the press release.
  • 6The filing includes standard signature and exhibit index sections.

Frequently Asked Questions

The main purpose of this 8-K filing by Biogen Idec Inc. on October 27, 2004, is to report on its Results of Operations and Financial Condition by furnishing a press release dated the same day. This is done under Item 2.02 of the Form 8-K.

The detailed financial results and operational information are not included directly in the 8-K filing itself. You will need to refer to Exhibit 99.1, which is the Press Release dated October 27, 2004, attached to this filing.

No, the press release furnished under Item 2.02 is specifically stated as not being 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, meaning it is not subject to the liabilities associated with that section, nor is it automatically incorporated by reference into other SEC filings.

The filing was signed by Thomas J. Bucknum, Executive Vice President, General Counsel, on behalf of Biogen Idec Inc.